Key result
Higher IGF-I levels linked to ~44% lower odds of arterial plaque per SD.
Cross-Sectional (n=310)
Yes
CONTEXT: Circulating IGF-I is inversely associated with ischemic heart disease incidence. Whether this association relates to alterations in plaque growth or stability, and the role of IGF-II and the major binding proteins [IGF binding protein (IGFBP)-2 and -3], is unclear. OBJECTIVE: Our objective was to test the hypothesis that circulating IGF-I is inversely, and IGF-II is positively, associated with subclinical atherosclerosis and plaque stability. DESIGN, SETTING, AND PARTICIPANTS: This was a cross-sectional analysis based on 310 participants in the United Kingdom-based Boyd Orr cohort who were aged 63-82 yr. Cohort members from Aberdeen, Bristol, Dundee, Wisbech, and London were invited to clinics for fasted venepuncture and arterial ultrasound examination. MAIN OUTCOMES: Arterial intima-media thickness, arterial plaque prevalence, and computerized assessment of plaque echogenicity (a measure of stability), undertaken using the gray scale median, were calculated. RESULTS: In total, 269 of 310 (86.8%) participants had at least one carotid or femoral plaque. In models controlling for IGFBP-3, there was a 44% (95% confidence interval 12-64%) reduction in the odds of any plaque and a 28% lower (0-48%) odds of echolucent (unstable) plaques per sd increase in IGF-I. IGFBP-3 was positively associated with plaque instability (odds ratio: 1.38; 0.99-1.93). IGF-II was positively associated (0.05-mm increase per sd; 95% confidence interval 0.01-0.09), and IGFBP-2 was inversely associated, with carotid bifurcation intima-media thickness. Neither IGF-II nor IGFBP-2 was associated with plaque prevalence or echogenicity. CONCLUSION: High-circulating IGF-I levels may promote arterial plaque stability. IGF-II and IGFBP-2 do not appear to play a role in plaque development or stability.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2008) conducted a cross-sectional in Subclinical atherosclerosis and plaque stability (n=310). Circulating IGF-I levels was evaluated on Arterial plaque prevalence (odds of any plaque per SD increase in IGF-I) (44% reduction in odds, 95% CI 12-64). Higher circulating IGF-I levels were associated with a 44% reduction in the odds of any arterial plaque (95% CI 12-64%) and a 28% lower odds of unstable plaques per SD increase.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: